AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
The drug helping Israeli pilots stay sharp on long missions over Iran
2
Iron Beam remains unused despite renewed drone threat from Iran and Lebanon
3
The only Israeli in Bahrain
4
As war threatens the Gulf economy, Israel’s defense edge gains value
5
“Iran’s attack on the Gulf states is going to be a bonanza for the Israeli defense industries”
More news

Zachy Hennessey

20 stories about Zachy Hennessey
Judah Taub, Managing Partner at Hetz Ventures.

“When Taiwan gets tense, every AI chip gets expensive. Companies building around that constraint will own the next decade.”

27.01.26|Zachy Hennessey, Elihay Vidal
Judah Taub, Managing Partner at Hetz Ventures, joined CTech for its 2026 VC Survey.
Gili Elkin, Founder & Managing Partner at ICI Fund.

“We’re entering a decade where intelligence extends beyond the screen into mission-critical, real-world environments”

26.01.26|Zachy Hennessey, Elihay Vidal
Gili Elkin, Founder & Managing Partner at ICI Fund, joined CTech for its 2026 VC Survey. 
Aaron Rinberg

“With LPs, the 2026 story isn’t a rebrand so much as a reframing: innovation plus extreme resilience”

25.01.26|Zachy Hennessey, Elihay Vidal
Aaron Rinberg, partner at Ibex Investors, joined CTech for its 2026 VC Survey. 
Dorin Baniel, principal & head of EMEA office at NightDragon.

“Israeli startup growth remains dependent on the US as investors, buyers, partners, and customers”

22.01.26|Zachy Hennessey, Elihay Vidal
Dorin Baniel, Partner, Israel, at NightDragon, joined CTech for its 2026 VC Survey. 
Amit Alfasi, Investor Relations Manager at Peregrine Ventures.

“The same sensor fusion and computer vision tech used for military target acquisition are now disrupting surgery”

21.01.26|Zachy Hennessey, Elihay Vidal
Amit Alfasi, investor relations manager at Peregrine Ventures, joined CTech for its 2026 VC Survey.  
Nadav Shimoni, Managing Director at A² Ventures.

“The winners won’t be the loudest or the most ambitious but the most focused, efficient, and boringly profitable”

20.01.26|Zachy Hennessey, Elihay Vidal
Nadav Shimoni, Managing Director at A² Ventures, joined CTech for its 2026 VC Survey.  
Lee Ben-Gal and Haim Bachar, Investors at lool ventures.

“AI is making output per person the real scaling metric; headcount growth is now often a lagging indicator.”

19.01.26|Zachy Hennessey, Elihay Vidal
Lee Ben-Gal and Haim Bachar, Investors at lool ventures, joined CTech for its 2026 VC Survey.  
Tzahi Weisfeld, co-founder & chairman at Ignite DeepTech.

“Israel’s best companies will still be global, but not hostage to any single platform or jurisdiction.”

18.01.26|Zachy Hennessey, Elihay Vidal
Tzahi Weisfeld, co-founder & chairman at Ignite DeepTech, joined CTech for its 2026 VC Survey.  
Ran Levitzky, general partner at Magenta Venture Partners.

“Most investors still treat AI and crypto as separate worlds. The real opportunity lies in the infrastructure layer that connects them.”

15.01.26|Zachy Hennessey, Elihay Vidal
Ran Levitzky, general partner at Magenta Venture Partners, joined CTech for its 2026 VC Survey. 
Prof. Lior Zalmanson, Coller School of Management at TAU.

"Israel would become a global AI powerhouse if it moved from inventing to owning and scaling"

14.01.26|Zachy Hennessey
What would it take to make Israel the world’s third AI power? 
Elle Taitou Spruch, senior investment associate at Planven.

“Innovation and resilience are not separate attributes of the Israeli tech ecosystem, they are structurally linked”

14.01.26|Zachy Hennessey, Elihay Vidal
Elle Taitou Spruch, senior investment associate at Planven, joined CTech for its 2026 VC Survey.  
Rotem Shacham, Director of PSG Equity.

"It’s no longer a question of if AI can deliver great efficiency gains but only a question of how much"

12.01.26|Zachy Hennessey, Elihay Vidal
PSG Equity director Rotem Shacham joined CTech for its 2026 VC Survey. 
Eyal Redler, managing partner at The Garage.

“AI agents are not replacing human judgment. They are replacing latency, manual execution, and coordination costs”

11.01.26|Zachy Hennessey, Elihay Vidal
Eyal Redler, managing partner at The Garage, joined CTech for its 2026 VC Survey.  
Renana Ashkenazi, managing partner at Grove Ventures.

“Everyone is obsessed with the AI Brain, but there’s a massive undervalued opportunity in the AI Body”

08.01.26|Zachy Hennessey, Elihay Vidal
Grove Ventures managing partner Renana Ashkenazi joined CTech for its 2026 VC Survey. 
Amir Tzach, Chief Investment Officer at InNegev.

“In the AI era, companies must demonstrate non-linear growth”

07.01.26|Zachy Hennessey, Elihay Vidal
InNegev Chief Investment Officer Amir Tzach joined CTech for its 2026 VC Survey. 
Ophir Shay, TLV Partners associate.

“In a world where cash is king and fundraising cycles are longer, companies with strong retention will be rewarded”

06.01.26|Zachy Hennessey, Elihay Vidal
TLV Partners associate Ophir Shay joined CTech for its 2026 VC Survey. 
Adi Gozes, AnD Ventures managing partner.

“The next generation of Israeli tech is emerging from a very different pipeline: ex-combat commanders”

05.01.26|Zachy Hennessey, Elihay Vidal
AnD Ventures managing partner Adi Gozes joined CTech for its 2026 VC Survey.
Shlomi Kofman, IIA VP & head of international collaborations division; Yariv Lotan, SNC VP of product and data.

“Health tech is nowhere near the ‘bottom of the well’ - we are just moving from hype to value”

24.12.25|Zachy Hennessey
After a sharp contraction in 2025, healthtech is entering an efficiency cycle where funding decisions are driven less by long-term promise and more by demonstrable, near-term return on investment. 
Eran Lerer; Mati Gill; Shai Policker.

Israeli healthtech faces a more selective funding market after the war

18.12.25|Zachy Hennessey
In a sector defined by long timelines, regulatory hurdles, and sustained capital needs, overseas investors have become more selective and more price-sensitive. 
Sai Jasti, senior VP and head of data science and AI at Bayer; Ofer Sharon, MD, physician and CEO of OncoHost

“Younger people are getting cancer more and more. We have to make kinder medicines.”

14.12.25|Zachy Hennessey
As AI hype accelerates, oncology’s real progress is happening quietly, driven by data, regulation, and the slow work of making cancer treatment more precise and sustainable 
Previous ArticlesMore Articles